Kuei-jen L Edenfield
Examiner (ID: 5120)
Most Active Art Unit | 2872 |
Art Unit(s) | 2872 |
Total Applications | 115 |
Issued Applications | 34 |
Pending Applications | 57 |
Abandoned Applications | 24 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 17997873
[patent_doc_number] => 11498967
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-11-15
[patent_title] => CD80 variant immunomodulatory proteins and uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/591499
[patent_app_country] => US
[patent_app_date] => 2022-02-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 13
[patent_no_of_words] => 79399
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 109
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17591499
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/591499 | CD80 variant immunomodulatory proteins and uses thereof | Feb 1, 2022 | Issued |
Array
(
[id] => 17314520
[patent_doc_number] => 20210403568
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-30
[patent_title] => BIOPHARMACEUTICAL FORMULATION OF ANTI-PD-1, ANTI-PD-L1, AND ANTI-VEGFR THERAPEUTIC MONOCLONAL ANTIBODIES AND METHOD FOR TREATING NSCLC BY INHALATION
[patent_app_type] => utility
[patent_app_number] => 17/362218
[patent_app_country] => US
[patent_app_date] => 2021-06-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9722
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 55
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17362218
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/362218 | BIOPHARMACEUTICAL FORMULATION OF ANTI-PD-1, ANTI-PD-L1, AND ANTI-VEGFR THERAPEUTIC MONOCLONAL ANTIBODIES AND METHOD FOR TREATING NSCLC BY INHALATION | Jun 28, 2021 | Abandoned |
Array
(
[id] => 19425104
[patent_doc_number] => 12084507
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-09-10
[patent_title] => Humanized anti-NGF antibodies and methods of treating pain thereof
[patent_app_type] => utility
[patent_app_number] => 17/197358
[patent_app_country] => US
[patent_app_date] => 2021-03-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 16
[patent_no_of_words] => 34528
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 74
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17197358
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/197358 | Humanized anti-NGF antibodies and methods of treating pain thereof | Mar 9, 2021 | Issued |
Array
(
[id] => 16977662
[patent_doc_number] => 20210221899
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-22
[patent_title] => Anti-NGF Antibodies and Methods Thereof
[patent_app_type] => utility
[patent_app_number] => 17/193544
[patent_app_country] => US
[patent_app_date] => 2021-03-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34382
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17193544
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/193544 | Anti-NGF Antibodies and Methods Thereof | Mar 4, 2021 | Pending |
Array
(
[id] => 16962951
[patent_doc_number] => 20210214450
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-15
[patent_title] => Anti-NGF Antibodies and Methods Thereof
[patent_app_type] => utility
[patent_app_number] => 17/191972
[patent_app_country] => US
[patent_app_date] => 2021-03-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34460
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17191972
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/191972 | Anti-NGF Antibodies and Methods Thereof | Mar 3, 2021 | Pending |
Array
(
[id] => 16868560
[patent_doc_number] => 20210162027
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-03
[patent_title] => BOTULINUM NEUROTOXIN FOR TREATMENT OF DISORDERS ASSOCIATED WITH MELANOCYTE HYPERACTIVITY AND/OR EXCESS MELANIN
[patent_app_type] => utility
[patent_app_number] => 17/166386
[patent_app_country] => US
[patent_app_date] => 2021-02-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7330
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17166386
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/166386 | BOTULINUM NEUROTOXIN FOR TREATMENT OF DISORDERS ASSOCIATED WITH MELANOCYTE HYPERACTIVITY AND/OR EXCESS MELANIN | Feb 2, 2021 | Abandoned |
Array
(
[id] => 16837945
[patent_doc_number] => 20210145957
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-20
[patent_title] => GROUP B STREPTOCOCCUS POLYSACCHARIDE-PROTEIN CONJUGATES, METHODS FOR PRODUCING CONJUGATES, IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATES, AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/161119
[patent_app_country] => US
[patent_app_date] => 2021-01-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 47444
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -39
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17161119
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/161119 | GROUP B STREPTOCOCCUS POLYSACCHARIDE-PROTEIN CONJUGATES, METHODS FOR PRODUCING CONJUGATES, IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATES, AND USES THEREOF | Jan 27, 2021 | Abandoned |
Array
(
[id] => 16791726
[patent_doc_number] => 20210121543
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-29
[patent_title] => SUTURE LINE ADMINISTRATION TECHNIQUE USING BOTULINUM TOXINS
[patent_app_type] => utility
[patent_app_number] => 17/119880
[patent_app_country] => US
[patent_app_date] => 2020-12-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14693
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 51
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17119880
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/119880 | SUTURE LINE ADMINISTRATION TECHNIQUE USING BOTULINUM TOXINS | Dec 10, 2020 | Abandoned |
Array
(
[id] => 16583210
[patent_doc_number] => 20210017612
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-01-21
[patent_title] => BACILLUS COMPOSITIONS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/034028
[patent_app_country] => US
[patent_app_date] => 2020-09-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11996
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17034028
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/034028 | BACILLUS COMPOSITIONS AND USES THEREOF | Sep 27, 2020 | Abandoned |
Array
(
[id] => 16673134
[patent_doc_number] => 20210061897
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-04
[patent_title] => Antibodies to TGF-Beta
[patent_app_type] => utility
[patent_app_number] => 16/997365
[patent_app_country] => US
[patent_app_date] => 2020-08-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20636
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16997365
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/997365 | Antibodies to TGF-Beta | Aug 18, 2020 | Abandoned |
Array
(
[id] => 16582837
[patent_doc_number] => 20210017239
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-01-21
[patent_title] => PROTEINS WITH DIAGNOSTIC AND THERAPEUTIC USES
[patent_app_type] => utility
[patent_app_number] => 16/995344
[patent_app_country] => US
[patent_app_date] => 2020-08-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24236
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 50
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16995344
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/995344 | PROTEINS WITH DIAGNOSTIC AND THERAPEUTIC USES | Aug 16, 2020 | Abandoned |
Array
(
[id] => 16581506
[patent_doc_number] => 20210015908
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-01-21
[patent_title] => METHODS FOR TREATING AND FOR INHIBITING PROGRESSION OF SEIZURES
[patent_app_type] => utility
[patent_app_number] => 16/921477
[patent_app_country] => US
[patent_app_date] => 2020-07-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10526
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16921477
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/921477 | METHODS FOR TREATING AND FOR INHIBITING PROGRESSION OF SEIZURES | Jul 5, 2020 | Abandoned |
Array
(
[id] => 16106787
[patent_doc_number] => 20200205416
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-02
[patent_title] => ALTERING MICROBIAL POPULATIONS & MODIFYING MICROBIOTA
[patent_app_type] => utility
[patent_app_number] => 16/818962
[patent_app_country] => US
[patent_app_date] => 2020-03-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 87490
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16818962
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/818962 | ALTERING MICROBIAL POPULATIONS & MODIFYING MICROBIOTA | Mar 12, 2020 | Abandoned |
Array
(
[id] => 16175545
[patent_doc_number] => 20200222513
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-16
[patent_title] => BOTULINUM TOXIN FOR SPASMOLYSIS IN REVASCULARIZATION
[patent_app_type] => utility
[patent_app_number] => 16/743881
[patent_app_country] => US
[patent_app_date] => 2020-01-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5917
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16743881
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/743881 | BOTULINUM TOXIN FOR SPASMOLYSIS IN REVASCULARIZATION | Jan 14, 2020 | Abandoned |
Array
(
[id] => 18793918
[patent_doc_number] => 11827670
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-11-28
[patent_title] => Anti-CfaE antibodies and methods of use
[patent_app_type] => utility
[patent_app_number] => 17/292078
[patent_app_country] => US
[patent_app_date] => 2019-11-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 21
[patent_no_of_words] => 23663
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 100
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17292078
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/292078 | Anti-CfaE antibodies and methods of use | Nov 11, 2019 | Issued |
Array
(
[id] => 17922826
[patent_doc_number] => 11466059
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-10-11
[patent_title] => Modified protein
[patent_app_type] => utility
[patent_app_number] => 15/733350
[patent_app_country] => US
[patent_app_date] => 2019-01-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 28
[patent_figures_cnt] => 22
[patent_no_of_words] => 11891
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 21
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15733350
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/733350 | Modified protein | Jan 8, 2019 | Issued |
Array
(
[id] => 16362450
[patent_doc_number] => 20200319201
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-08
[patent_title] => METHODS FOR MONITORING TUBERCULOSIS MEDICATION
[patent_app_type] => utility
[patent_app_number] => 16/955503
[patent_app_country] => US
[patent_app_date] => 2018-12-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4832
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 14
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16955503
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/955503 | METHODS FOR MONITORING TUBERCULOSIS MEDICATION | Dec 17, 2018 | Abandoned |
Array
(
[id] => 16673429
[patent_doc_number] => 20210062192
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-04
[patent_title] => IMMUNOSTIMULATORY OLIGONUCLEOTIDES
[patent_app_type] => utility
[patent_app_number] => 16/771789
[patent_app_country] => US
[patent_app_date] => 2018-12-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31568
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16771789
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/771789 | IMMUNOSTIMULATORY OLIGONUCLEOTIDES | Dec 6, 2018 | Abandoned |
Array
(
[id] => 16899041
[patent_doc_number] => 20210177957
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-17
[patent_title] => COMPOSITIONS COMPRISING STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE-PROTEIN CONJUGATES AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/769874
[patent_app_country] => US
[patent_app_date] => 2018-12-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 58196
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -57
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16769874
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/769874 | COMPOSITIONS COMPRISING STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE-PROTEIN CONJUGATES AND METHODS OF USE THEREOF | Dec 3, 2018 | Abandoned |
Array
(
[id] => 17458597
[patent_doc_number] => 20220071901
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-10
[patent_title] => A LIQUID FORMULATION OF HUMANIZED ANTIBODY FOR TREATING IL-6-MEDIATED DISEASES
[patent_app_type] => utility
[patent_app_number] => 16/337372
[patent_app_country] => US
[patent_app_date] => 2018-11-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14111
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 145
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16337372
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/337372 | A LIQUID FORMULATION OF HUMANIZED ANTIBODY FOR TREATING IL-6-MEDIATED DISEASES | Nov 29, 2018 | Abandoned |